HealthEquity (NASDAQ:HQY) Price Target Increased to $107.00 by Analysts at Wells Fargo & Company

HealthEquity (NASDAQ:HQYFree Report) had its price objective raised by Wells Fargo & Company from $105.00 to $107.00 in a research report report published on Tuesday morning, Benzinga reports. The brokerage currently has an overweight rating on the stock.

Several other brokerages have also issued reports on HQY. KeyCorp raised their price objective on HealthEquity from $85.00 to $95.00 and gave the stock an overweight rating in a report on Friday, March 22nd. JMP Securities raised their price target on HealthEquity from $101.00 to $105.00 and gave the stock a market outperform rating in a report on Tuesday. Barclays raised their price target on HealthEquity from $84.00 to $104.00 and gave the stock an overweight rating in a report on Friday, February 23rd. JPMorgan Chase & Co. raised their price target on HealthEquity from $86.00 to $108.00 and gave the stock an overweight rating in a report on Tuesday, April 2nd. Finally, Robert W. Baird raised their price target on HealthEquity from $98.00 to $104.00 and gave the stock an outperform rating in a report on Tuesday. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of Moderate Buy and an average target price of $100.17.

Get Our Latest Report on HealthEquity

HealthEquity Price Performance

HQY stock opened at $83.40 on Tuesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.76 and a quick ratio of 4.76. The business has a 50 day simple moving average of $79.57 and a 200-day simple moving average of $76.01. The firm has a market capitalization of $7.26 billion, a PE ratio of 130.31, a price-to-earnings-growth ratio of 1.19 and a beta of 0.55. HealthEquity has a 1 year low of $57.97 and a 1 year high of $85.71.

HealthEquity (NASDAQ:HQYGet Free Report) last released its quarterly earnings results on Tuesday, March 19th. The company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.08. HealthEquity had a return on equity of 6.91% and a net margin of 5.57%. The company had revenue of $262.39 million for the quarter, compared to analysts’ expectations of $258.56 million. Equities research analysts anticipate that HealthEquity will post 2.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Evelyn S. Dilsaver sold 32,500 shares of the business’s stock in a transaction dated Tuesday, March 26th. The stock was sold at an average price of $79.29, for a total transaction of $2,576,925.00. Following the completion of the transaction, the director now owns 32,123 shares of the company’s stock, valued at approximately $2,547,032.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Evelyn S. Dilsaver sold 32,500 shares of the company’s stock in a transaction that occurred on Tuesday, March 26th. The stock was sold at an average price of $79.29, for a total value of $2,576,925.00. Following the sale, the director now directly owns 32,123 shares in the company, valued at approximately $2,547,032.67. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Jon Kessler sold 33,765 shares of the company’s stock in a transaction that occurred on Friday, March 22nd. The shares were sold at an average price of $79.81, for a total value of $2,694,784.65. Following the completion of the sale, the chief executive officer now owns 126,635 shares in the company, valued at $10,106,739.35. The disclosure for this sale can be found here. Insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Lindbrook Capital LLC raised its stake in HealthEquity by 22.7% during the 1st quarter. Lindbrook Capital LLC now owns 698 shares of the company’s stock worth $57,000 after buying an additional 129 shares during the period. Xponance Inc. increased its holdings in HealthEquity by 1.2% during the 4th quarter. Xponance Inc. now owns 12,269 shares of the company’s stock worth $813,000 after purchasing an additional 147 shares in the last quarter. O Shaughnessy Asset Management LLC increased its holdings in HealthEquity by 3.9% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 5,219 shares of the company’s stock worth $426,000 after purchasing an additional 197 shares in the last quarter. KLR Investment Advisors LLC increased its holdings in HealthEquity by 4.2% during the 4th quarter. KLR Investment Advisors LLC now owns 5,914 shares of the company’s stock worth $392,000 after purchasing an additional 241 shares in the last quarter. Finally, Capstone Investment Advisors LLC increased its holdings in HealthEquity by 7.0% during the 4th quarter. Capstone Investment Advisors LLC now owns 3,710 shares of the company’s stock worth $246,000 after purchasing an additional 243 shares in the last quarter. Institutional investors and hedge funds own 99.55% of the company’s stock.

HealthEquity Company Profile

(Get Free Report)

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Recommended Stories

Analyst Recommendations for HealthEquity (NASDAQ:HQY)

Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.